



JC04 Rec'd PCT/PTO 24 JUN 2005

PCT #3

Practitioner's Docket No. 2002DE113

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Heinrichs et al.

Application No.: 10/517,117

Group No.:

Filed: December 3, 2004

For: Conversion Products of Mixtures Of Long-Chain Fatty Acids And Aliphatic Diamines, And the Use Thereof

Commissioner for Patent
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

CERTIFICATION UNDER 37 C.F.R. Sections 1.8(a) and 1.10*
(When using Express Mail, the Express Mail label number is *mandatory*;
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

X

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. section 1.8(a)

X

with sufficient postage as first class mail.

37 C.F.R. section 1.10*

[] as "Express Mail Post Office to Address"
Mailing Label No. _____ (mandatory)

TRANSMISSION

[] transmitted by facsimile to the Patent and Trademark Office (703) ____-____.

Date:

June 22, 2005

Signature

Jackie L. Wise

Jackie L. Wise
(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b).
"Since the filing of correspondence under [section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Dear Sir:

In accordance with the duty of disclosure provisions of 37 CFR §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than search report(s) from a counterpart foreign application or a PCT International Search Report, if submitted herewith).

1. ☒ Enclosures accompanying this Information Disclosure Statement are:
 - 1a. ☒ Form PTO-1449.
 - 1b. ☒ Copies of Information Disclosure Statement citations.
 - 1c. ☐ PCT Search Report
 - 1d. ☐ Copies of Co-pending U.S. Applications.
2. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(b) with the filing of the U.S. patent application. Accordingly, no fee or §1.97(e) Statement is required.
3. ☒ This Information Disclosure Statement is filed under 37 CFR §1.97(b) before the latter of three months after the U.S. patent application filing date or the first Office Action on the merits. Accordingly, no fee or §1.97(e) Statement is required.
4. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(c) after the first Office Action on the merits, but before a Final Office Action or a Notice of Allowance. The \$180.00 fee set forth in 37 CFR §1.17(p) in accordance with 37 CFR §1.97(c) is to be charged to Deposit Account No. 03-2060.
5. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(e) in that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Accordingly, no fee is required.
6. ☐ This Information Disclosure Statement is filed in conjunction with a Request For Continued Examination. Accordingly, no fee or §1.97(e) Statement is required.

7. ☒ The English language documents identified by reference in the TRANSLATION Section of the foreign patents list of the attached 1449 Form are believed to be a concise statement, or the equivalent or substantial equivalent to the foreign language documents cited in the attached 1449 Form.
8. ☐ In addition to the documents cited, the Office's attention is directed to the following co-pending U.S. Application Serial Number(s), copies of which are attached for the convenience of the Office:

Respectfully submitted,



Anthony A. Bisulca
Registration No. 40,913

CUSTOMER NO. 25,255

Clariant Corporation
Industrial Property Department
4000 Monroe Road
Charlotte, North Carolina 28205
Telephone: 704/331-7151
Facsimile: 704/331-7707

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 2002DE113	SERIAL NO. 10/517,117
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		
(37 CFR 1.98(b))		
APPLICANT: Heinrichs et al.		
FILING DATE: 12/3/2004	GROUP:	

U.S. PATENT DOCUMENTS

Examiner Initial		Patent Number	Issue Dte	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	2901370	8/25/59	Kent et al.			
	AB	3038815	6/12/62	Kaupp et al.			
	AC						
FOREIGN PATENT OR PUBLISHED FOREIGN APPLICATION							
		DOCUMENT NUMBER	PUB. DATE	COUNTRY			TRANSLATION
	BA	DE 2730175	1/10/78	Germany			English Abstract
	BB	DE 19929962	1/11/01	Germany			English Abstract
	BC	WO 0068329	11/16/00	WIPO			English
	BD	DE 934767	1/3/55	Germany			English Abstract
	BE	DE 932965	9/12/55	Germany			English Abstract
	BF	GB 677935	8/27/52	Great Britian			English
	BG	DE 1096603	1/5/61	Germany			See AB above
	BH	FR 2765229	12/31/98	France			English Abstract
	BI						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication**)

CA	PCT ISR for PCT/EP03/05670, mailed 1/09/2003		
CB	English Translation of PCT IPER PCT//EP03/05670, 9/8/2004		
CC	German Office Action for DE 10224847.8, 12/8/2004		
CD	Chem. Abstr. 80:26780 (1974)		
CE	German Office Action for DE 10224847.8, 2/6/2003		
CF			
CG			
CH			
CI			
<table border="1"> <tr> <td>EXAMINER</td> <td>DATE CONSIDERED</td> </tr> </table>		EXAMINER	DATE CONSIDERED
EXAMINER	DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			